Hepatocellular Carcinoma (HCC)
Conditions
Interventions
Experimental group:Exploratory Study of Preoperative Transarterial Chemoembolization for Treatment-Na?ve, Resectable Hepatocellular Carcinoma
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18 years or older; 2. Patients with clinically diagnosed hepatocellular carcinoma (HCC); 3. Treatment-naïve patients scheduled for hepatic resection after multidisciplinary team (MDT) discussion; 4. With an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; 5. Adequate future liver remnant (FLR) volume/function; 6. Patients must have adequate bone marrow reserve function and/or no impairment of liver, kidney, or coagulation functions. 7. Patients voluntarily provide written informed consent and are expected to have good compliance.
Exclusion criteria
Exclusion criteria: 1. Known or suspected allergy/hypersensitivity to contrast agents, epirubicin, or any of their analogues/excipients. 2. Active infections with human immunodeficiency virus (HIV), syphilis, or hepatitis C virus (HCV). Active HCV infection is defined as being anti-HCV antibody positive with detectable HCV RNA. Active HIV infection is defined as being HIV antibody positive. 3. Histological type other than hepatocellular carcinoma (HCC); 4. Deemed by the investigator to be unsuitable for participation in the trial for any reason;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-Free Survival;Progression-Free Survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Microvascular Invasion Rate;R0 Resection Rate;Major Pathological Response Rate;Overall Survival;Pathological Complete Response Rate; | — |
Countries
China
Contacts
Public ContactJiansong Ji
Lishui Central Hospital
Outcome results
None listed